Press Releases May 15, 2026 08:59 AM

LINKAGE GLOBAL TO CHANGE NASDAQ TICKER SYMBOL TO “UZX” FOLLOWING TRANSACTION WITH UZX DAO FOUNDATION

Linkage Global to change its Nasdaq ticker to UZX following strategic transaction with UZX DAO Foundation to integrate AI and digital asset technologies.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
UZX

Linkage Global Inc. announced it will change its Nasdaq ticker symbol from LGCB to UZX effective May 18, 2026, reflecting a fundamental shift in its business model after a token purchase transaction with UZX DAO Foundation. The partnership aims to integrate UZX DAO's AI technology and digital asset ecosystem into Linkage Global's cross-border e-commerce platform, enhancing services and expanding capabilities.

LINKAGE GLOBAL TO CHANGE NASDAQ TICKER SYMBOL TO “UZX” FOLLOWING TRANSACTION WITH UZX DAO FOUNDATION
UZX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Linkage Global changes Nasdaq ticker from LGCB to UZX to reflect new strategic direction.
  • Transaction with UZX DAO Foundation enables integration of AI and digital asset technology into cross-border e-commerce platform.
  • The partnership supports the expansion and enhancement of Linkage Global's service offering in international e-commerce and crypto sectors.

New York, NY, May 15, 2026 (GLOBE NEWSWIRE) -- Linkage Global Inc. (NASDAQ: LGCB) (“Linkage Global” or the “Company”), a public company that engages in providing cross-border e-commerce integrated services, today announced that it would change its Nasdaq ticker symbol from “LGCB” to “UZX,” effective May 18, 2026. The Company’s Class A ordinary shares will begin trading under the new ticker symbol, UZX, on the Nasdaq Capital Market on May 18, 2026.

The ticker change is part of a proposed fundamental evolution in Linkage Global’s business model. It follows the Company’s token purchase transaction with UZX DAO Foundation, an exempt entity incorporated under the laws of the Cayman Islands, and certain holders of units of the UZX Token, that was consummated on April 8, 2026. The Company and UZX DAO Foundation plan to further the partnership by integrating UZX DAO Foundation’s artificial intelligence technology and digital asset ecosystem into the Company existing cross-border e-commerce platform infrastructure.

In connection with the ticker change, no action is required from the Company’s current shareholders and the Company’s CUSIP number will remain the same.

About Linkage Global Inc.

Linkage Global Inc. (NASDAQ: LGCB) is a holding company, which engages in providing cross-border e-commerce integrated services. Through its operating entities, it developed a comprehensive service system comprised of two lines of business complementary to each other, including cross-border sales and integrated e-commerce services. It operates through the Extend and Other Subsidiaries segments. The company was founded on March 24, 2022, and is headquartered in Tokyo, Japan.

About UZX DAO Foundation

Founded in 2023, UZX DAO Foundation is the world’s first DAO-driven cryptocurrency exchange. UZX DAO Foundation is committed to empowering global traders on a secure and transparent platform that ensures safe, stable trading. Governed by the UZX DAO through a Cayman Foundation, the platform prioritizes decentralized decision-making to build an inclusive, secure financial ecosystem offering diverse investment services for the crypto world. Management team of UZX DAO Foundation hails from multiple countries and regions, with core members bringing extensive experience from leading institutions such as Coinbase, Binance, Morgan Stanley, Amazon, and Google, providing strong global strategic operations and deep expertise in financial risk management.

Safe Harbor Statement

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “assesses,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may,” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s annual reports on Form 20-F and other filings with the U.S. Securities and Exchange Commission.

IR Contact:
Annabelle Zhang
International Elite Capital 
management@iecapitalusa.com 


Risks

  • Execution risk in integrating AI and digital asset systems into existing e-commerce infrastructure.
  • Regulatory uncertainties related to cryptocurrency and digital asset operations, particularly involving DAO structures.
  • Market adoption risks for the updated platform and services amid competitive cross-border e-commerce and crypto markets.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026